3 Drugs Stocks On The Rise

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

One out of the three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 15 points (0.1%) at 17,122 as of Wednesday, Aug. 27, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,632 issues advancing vs. 1,319 declining with 192 unchanged.

The Drugs industry currently sits up 0.2% versus the S&P 500, which is unchanged. A company within the industry that increased today was Grifols ( GRFS), up 2.1%. On the negative front, top decliners within the industry include Bristol-Myers Squibb Company ( BMY), down 1.0%, and Celgene ( CELG), down 0.7%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. GlaxoSmithKline ( GSK) is one of the companies pushing the Drugs industry higher today. As of noon trading, GlaxoSmithKline is up $0.41 (0.8%) to $48.67 on average volume. Thus far, 1.3 million shares of GlaxoSmithKline exchanged hands as compared to its average daily volume of 3.2 million shares. The stock has ranged in price between $48.56-$48.82 after having opened the day at $48.62 as compared to the previous trading day's close of $48.26.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

GlaxoSmithKline plc creates, discovers, develops, manufactures, and markets pharmaceutical products, such as vaccines, over-the-counter medicines, and health-related consumer products worldwide. GlaxoSmithKline has a market cap of $115.6 billion and is part of the health care sector. Shares are down 9.6% year-to-date as of the close of trading on Tuesday. Currently there is 1 analyst who rates GlaxoSmithKline a buy, 1 analyst rates it a sell, and 6 rate it a hold.

TheStreet Ratings rates GlaxoSmithKline as a buy. The company's strengths can be seen in multiple areas, such as its notable return on equity and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full GlaxoSmithKline Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Pfizer ( PFE) is up $0.28 (1.0%) to $29.50 on average volume. Thus far, 11.7 million shares of Pfizer exchanged hands as compared to its average daily volume of 23.3 million shares. The stock has ranged in price between $29.36-$29.57 after having opened the day at $29.47 as compared to the previous trading day's close of $29.21.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines, and various consumer healthcare products. Pfizer has a market cap of $183.3 billion and is part of the health care sector. Shares are down 4.6% year-to-date as of the close of trading on Tuesday. Currently there are 7 analysts who rate Pfizer a buy, 1 analyst rates it a sell, and 4 rate it a hold.

TheStreet Ratings rates Pfizer as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, expanding profit margins, good cash flow from operations and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Pfizer Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Gilead ( GILD) is up $2.12 (2.0%) to $108.38 on heavy volume. Thus far, 9.4 million shares of Gilead exchanged hands as compared to its average daily volume of 12.0 million shares. The stock has ranged in price between $105.76-$108.77 after having opened the day at $106.55 as compared to the previous trading day's close of $106.27.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines for the treatment of life threatening diseases in North America, South America, Europe, and the Asia-Pacific. Gilead has a market cap of $162.4 billion and is part of the health care sector. Shares are up 41.5% year-to-date as of the close of trading on Tuesday. Currently there are 13 analysts who rate Gilead a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Gilead as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, impressive record of earnings per share growth, compelling growth in net income and notable return on equity. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Gilead Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

Italian Bonds Slump as Government Mulls Anti-Euro Finance Minister

Italian Bonds Slump as Government Mulls Anti-Euro Finance Minister

Global Stocks Hold Gains as North Korea Response on Talks Soothes Nerves

Global Stocks Hold Gains as North Korea Response on Talks Soothes Nerves

Canopy Growth Lets Down Eager Pot Investors; PayPal Keeps Dominating -- ICYMI

Canopy Growth Lets Down Eager Pot Investors; PayPal Keeps Dominating -- ICYMI

Dow, S&P 500 and Nasdaq Tumble After Trump Calls Off North Korea Summit

Dow, S&P 500 and Nasdaq Tumble After Trump Calls Off North Korea Summit

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)